Study S001527

Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05254314
Acronym: GATA-3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 100
Start: 2022-10-11
Primary completion: 2026-09-28
Lead sponsor: Vanderbilt University Medical Center
Conditions: Asthma
Interventions: DRUG:Semaglutide Pen Injector 2.4mg weekly; OTHER:Placebo
Results posted: FALSE
Secondary identifiers: NIH:U01AI155299

Registered primary outcomes

The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity. [Baseline to week 12]
The impact of semaglutide once weekly on serum periostin in subjects with symptomatic, persistent asthma and obesity. [Baseline to week 4]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012497	Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma. Tomasello A, The journal of allergy and clinical immunology. Global	2026	Randomized trial	PMID 41567689 DOI	cites ClinicalTrials.gov:NCT05254314; registry reference DERIVED:41567689